Seroatlas · Human Serome Atlas

NPY2R

Neuropeptide Y receptor type 2

Also known as: NPY2R_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P49146
Gene: NPY2R
Ensembl: ENSG00000185149
Chromosome: 4
Canonical length: 381 aa
Protein class: G-protein coupled receptors, Predicted membrane proteins, Transporters

OverviewNCBI Gene

Predicted to enable calcium channel regulator activity and neuropeptide Y receptor activity. Involved in cardiac left ventricle morphogenesis and outflow tract morphogenesis. Located in cilium. Implicated in Huntington's disease; morbid obesity; and obesity. Biomarker of peripheral artery disease and temporal lobe epilepsy. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

381 residues, UniProt reviewed canonical sequence.

>P49146|NPY2R
     1  MGPIGAEADE NQTVEEMKVE QYGPQTTPRG ELVPDPEPEL IDSTKLIEVQ VVLILAYCSI
    61  ILLGVIGNSL VIHVVIKFKS MRTVTNFFIA NLAVADLLVN TLCLPFTLTY TLMGEWKMGP
   121  VLCHLVPYAQ GLAVQVSTIT LTVIALDRHR CIVYHLESKI SKRISFLIIG LAWGISALLA
   181  SPLAIFREYS LIEIIPDFEI VACTEKWPGE EKSIYGTVYS LSSLLILYVL PLGIISFSYT
   241  RIWSKLKNHV SPGAANDHYH QRRQKTTKML VCVVVVFAVS WLPLHAFQLA VDIDSQVLDL
   301  KEYKLIFTVF HIIAMCSTFA NPLLYGWMNS NYRKAFLSAF RCEQRLDAIH SEVSVTFKAK
   361  KNLEVRKNSG PNDSFTEATN V

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NPY2R can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 1.8 nTPM

Expression across tissuesHPA

Tissue

hypothalamus: 1.8 nTPM
breast: 1.6 nTPM
basal ganglia: 1.4 nTPM
hippocampal formation: 1.4 nTPM
cerebral cortex: 1 nTPM
amygdala: 0.9 nTPM

Single-cell type

leydig cells: 0.1 nCPM
adipocytes: 0 nCPM
adrenal cortex cells: 0 nCPM
adrenal medulla cells: 0 nCPM
alveolar cells type 1: 0 nCPM
alveolar cells type 2: 0 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

hippocampal formation: 12 nTPM
hypothalamus: 8.9 nTPM
cerebral cortex: 6.1 nTPM
amygdala: 4.8 nTPM
medulla oblongata: 3.7 nTPM
basal ganglia: 2.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.88
gnomAD pLI: 0.04
gnomAD missense Z: 0.81
DepMap mean gene effect: 0.17
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

G protein-coupled receptor, rhodopsin-like
Neuropeptide Y receptor family
GPCR, rhodopsin-like, 7TM
7 transmembrane receptor (rhodopsin family)
Neuropeptide Y2 receptor

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NPY2R as an antibody target. Whether an autoantibody or antibody against NPY2R could matter depends on whether native NPY2R is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NPY2R is annotated at the cell surface, where native NPY2R is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label NPY2R as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...